On March 30, 2026, Oncotelic Therapeutics, Inc. submitted a Form 8-K to the SEC, detailing other events and financial statements as part of its ongoing regulatory compliance. The filing, accepted on March 27, 2026, includes information pertinent to the company's operations and financial performance for the period ending March 23, 2026. The report is categorized under Item 8.01, which addresses other events, and Item 9.01, which covers financial statements and exhibits. This filing is part of the company's routine disclosures and does not indicate any significant changes or developments that would materially affect its stock price. The documents submitted include various exhibits, such as financial statements and graphical representations, which provide further insights into the company's financial health. Investors and stakeholders are encouraged to review the complete filing available on the SEC's EDGAR database for detailed information. The filing reflects Oncotelic's commitment to transparency and adherence to regulatory requirements, ensuring that all relevant information is disclosed to the public and investors alike.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.